Pharmacoeconomic review report : indication : secondary-progressive multiple sclerosis. Siponimod (Mayzent) (Novartis pharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

CADTH common drug review.

CADTH Common Drug Review

Language:

English

Subjects (All):

Multiple sclerosis--Treatment.

Multiple sclerosis.

Physical Description:

1 online resource (33 pages) : illustrations.

Edition:

Version: Final.

Place of Publication:

Ottawa (ON): : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

Siponimod (Mayzent) is a sphingosine 1-phosphate receptor modulator. This submission relates to the Health Canada-approved indication for the treatment of adults with secondary-progressive multiple sclerosis (SPMS) with active disease, evidenced by relapses or imaging features characteristic of multiple sclerosis (MS) inflammatory activity, to delay the progression of physical disability. Siponimod is available as 0.25 mg and 2 mg film-coated tablets. Treatment has to be initiated over five days: dose titration starts with 0.25 mg once daily on day 1 and day 2, followed by once daily doses of 0.5 mg on day 3 (two tablets of 0.25 mg), 0.75 mg on day 4 (three tablets of 0.25 mg), and 1.25 mg on day 5 (five tablets of 0.25 mg), to reach the maintenance dose of 2 mg siponimod. If a titration dose is missed on one day during the first six days of treatment, treatment needs to be re-initiated. At the submitted prices of 22.39 per 0.25 mg and

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of Sponsor's Pharmacoeconomic Submission

Sponsor's Base Case

Summary of Sponsor's Sensitivity Analyses

Limitations of Sponsor's Submission

CADTH Reanalyses

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Additional Information

Appendix 3. Summary of Other Health Technology Assessment Reviews of Drug

Appendix 4. Reviewer Worksheets

References.

Notes:

Includes bibliographical referneces.

Description based on publisher supplied metadata and other sources.